---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-078084"
form_type: "8-K"
ticker: null
cik: "0001808865"
company_name: "iTeos Therapeutics, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:31:52.582591+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# iTeos Therapeutics to wind down operations after terminating belrestotug program and GSK collaboration

## Summary
- Will wind down operations; expects severance charges of $21.8M-$24.7M and other program wind-down costs of $11.1M.
- Exploring potential asset sales including EOS-984, EOS-215, and preclinical obesity program targeting ENT1.
- Wind down substantially complete in Q3 2025; clinical development programs to wind down thereafter.
- Amended employment agreements for CEO, COO, CMO with enhanced severance if terminated during change in control (excluding dissolution).

## SEC filing metadata
- accession: 0000950170-25-078084
- form_type: 8-K
- cik: 0001808865
- company_name: iTeos Therapeutics, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/0000950170-25-078084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/itos-20250527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-078084
- JSON: https://secwatch.observer/filing/0000950170-25-078084.json
- Plain text: https://secwatch.observer/filing/0000950170-25-078084.txt

## Key facts
- Restructurings & Charges
  iTeos Therapeutics, Inc. announced a restructuring with charges of $21.8 million to $24.7 million affecting Company-wide (clinical and operational activities).
  - Type: restructuring
  - Charge: $21.8 million to $24.7 million
  - Affected area: Company-wide (clinical and operational activities)
  source text: The Company expects to incur charges in connection with the wind down consisting of (i) severance and other termination costs related to employees who would be terminated of approximately $21.8 million to $24.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/0000950170-25-078084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.